Atlas Trials

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Clinical trial NCT05837052 · RECRUITING

Trial details

NCT number
NCT05837052
Sponsor
Zhejiang University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Lung Non-Small Cell Carcinoma
Start date
2023-05-15
Primary completion
2025-06-30
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.